Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

AlzeCure Pharma’s CEO Martin Jönsson.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

A Growing Arts and Cultural Scene in Flemingsberg

As Flemingsberg transforms into a city, a vibrant and dynamic arts and cultural scene is essential. Last spring, for the first time, over thirty individuals active in the cultural sector with ties to Flemingsberg gathered. This marked the starting point for a growing cultural cluster within one of Sweden's largest urban development projects.

Agnes Török: A Voice for Performance Poetry & Reading Promotion

With roots in Sweden and an international career, Agnes Török has established themselves as one of the most engaging voices in modern poetry. Agnes Török is Sweden's Reading Ambassador, a spoken word poet, and an author. Recently, they were also appointed as the lead instructor for the new university program in Performance Poetry and Storytelling at the Stockholm Institute of Music Education (SMI).

ATMP Symposium for Knowledge Exchange, Innovation, and Future Collaborations

On January 22, 2025, NextGenNK and CCRM Nordic hosted a mini-symposium at Karolinska Institutet, Campus Flemingsberg, with a focus on Advanced Therapy Medicinal Products (ATMP). The event aimed to foster networking within the ATMP field and provide insights into both academic and commercial advancements in Stockholm and Sweden.